Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Arellano

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Nature Communications|May 9, 2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformationTaro Hitosugi, Lu Zhou, Jun Fan, et al.
Molecular Cell|November 22, 2016
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor GrowthJun Fan, Ruiting Lin, Siyuan Xia, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Nature Communications|May 9, 2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformationTaro Hitosugi, Lu Zhou, Jun Fan, et al.
Molecular Cell|November 22, 2016
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor GrowthJun Fan, Ruiting Lin, Siyuan Xia, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Blood|April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Lancet (London, England)|June 7, 2021
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 12